{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:04:38Z","timestamp":1787022278435,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":97,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.14283\/jpad.2024.115","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T02:03:11Z","timestamp":1718330591000},"page":"1251-1259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Alzheimer's Disease Linkage to Real-World Evidence (AD-LINE) Study: Linking Claims Data to Phase 3 GRADUATE Study of Gantenerumab"],"prefix":"10.1016","volume":"11","author":[{"given":"H.","family":"Fillit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Seleri Assun\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Majda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.D.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.M.","family":"To","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.M.","family":"Abbass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Raimundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.V.","family":"Tcheremissine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.14283\/jpad.2024.115_bib1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3233\/JAD-215710","article-title":"Retaining participants in longitudinal studies of Alzheimer's disease","volume":"87","author":"Gabel","year":"2022","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"10.14283\/jpad.2024.115_bib2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/alz.12737","article-title":"Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials","volume":"19","author":"Langbaum","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.14283\/jpad.2024.115_bib3","first-page":"386","article-title":"The inclusion of economic endpoints as outcomes in clinical trials reported to ClinicalTrials.gov","volume":"26","author":"Mitchell","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.14283\/jpad.2024.115_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cpt.2480","article-title":"Use of real-world evidence to drive drug development strategy and inform clinical trial design","volume":"111","author":"Dagenais","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.14283\/jpad.2024.115_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cpt.2474","article-title":"The role of real-world evidence in FDA-approved new drug and biologics license applications","volume":"111","author":"Purpura","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.14283\/jpad.2024.115_bib6","author":"US Food and Drug Administration"},{"issue":"1","key":"10.14283\/jpad.2024.115_bib7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1740774518815653","article-title":"Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomes","volume":"16","author":"Hay","year":"2019","journal-title":"Clin Trials"},{"issue":"8","key":"10.14283\/jpad.2024.115_bib8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s12603-010-0310-8","article-title":"Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease","volume":"14","author":"Fillit","year":"2010","journal-title":"J Nutr Health Aging"},{"key":"10.14283\/jpad.2024.115_bib9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.trci.2019.04.003","article-title":"Analysis of dementia in the US population using Medicare claims: Insights from linked survey and administrative claims data","volume":"5","author":"Chen","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"10.14283\/jpad.2024.115_bib10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40744-021-00302-2","article-title":"Probabilistic linkage of randomized controlled trial data to administrative claims: a case study of patients from baricitinib clinical trials","volume":"8","author":"McGuiness","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.14283\/jpad.2024.115_bib11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ahj.2019.09.002","article-title":"Claims-based cardiovascular outcome identification for clinical research: results from 7 large randomized cardiovascular clinical trials","volume":"218","author":"Brennan","year":"2019","journal-title":"Am Heart J"},{"issue":"7","key":"10.14283\/jpad.2024.115_bib12","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1161\/CIRCULATIONAHA.118.035236","article-title":"Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at intermediate risk","volume":"139","author":"Baron","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.14283\/jpad.2024.115_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s41669-020-00221-y","article-title":"Real-world evidence: bridging gaps in evidence to guide payer decisions","volume":"5","author":"Roberts","year":"2021","journal-title":"Pharmacoecon Open"},{"key":"10.14283\/jpad.2024.115_bib14","author":"Eckrote"},{"key":"10.14283\/jpad.2024.115_bib15","first-page":"692","article-title":"The impact of name transformation on match rates within a large consumer database","volume":"2022","author":"Leshin","year":"2023","journal-title":"AMIA Annu Symp Proc"},{"key":"10.14283\/jpad.2024.115_bib17","author":"Weng"},{"issue":"8","key":"10.14283\/jpad.2024.115_bib18","doi-asserted-by":"crossref","first-page":"e186019","DOI":"10.1001\/jamanetworkopen.2018.6019","article-title":"Assessment of long-term follow-up of randomized trial participants by linkage to routinely collected data: a scoping review and analysis","volume":"1","author":"Fitzpatrick","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.14283\/jpad.2024.115_bib19","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/alz.12362","article-title":"Population estimate of people with clinical ad and mild cognitive impairment in the United States (2020\u20132060)","volume":"17","author":"Rajan","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.14283\/jpad.2024.115_bib20","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/alz.12822","article-title":"Estimating prevalence of early Alzheimer's disease in the United States, accounting for racial and ethnic diversity","volume":"19","author":"Gillis","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2024.115_bib21","author":"Alzheimer's Association"},{"issue":"2","key":"10.14283\/jpad.2024.115_bib22","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40120-022-00335-x","article-title":"The humanistic and economic burden of Alzheimer's disease","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther"},{"issue":"8","key":"10.14283\/jpad.2024.115_bib23","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/jgs.14227","article-title":"Medicare expenditures of individuals with Alzheimer's disease and related dementias or mild cognitive impairment before and after diagnosis","volume":"64","author":"Lin","year":"2016","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.14283\/jpad.2024.115_bib24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/WAD.0000000000000262","article-title":"Relationships between cognitive complaints and quality of life in older adults with mild cognitive impairment, mild Alzheimer disease dementia, and normal cognition","volume":"32","author":"Stites","year":"2018","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"10","key":"10.14283\/jpad.2024.115_bib25","doi-asserted-by":"crossref","first-page":"e2129392","DOI":"10.1001\/jamanetworkopen.2021.29392","article-title":"Evaluation of the cost-effectiveness of drug treatment for Alzheimer disease in a simulation model that includes caregiver and societal factors","volume":"4","author":"Ito","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.14283\/jpad.2024.115_bib26","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40120-023-00460-1","article-title":"estimated societal value of lecanemab in patients with early Alzheimer's disease using simulation modeling","volume":"12","author":"Tahami Monfared","year":"2023","journal-title":"Neurol Ther"},{"issue":"20","key":"10.14283\/jpad.2024.115_bib27","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer's disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.14283\/jpad.2024.115_bib28","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13195-022-01110-8","article-title":"Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease","volume":"14","author":"Bateman","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2024.115_bib29","author":"Research Data Assistance Center (ResDAC)"},{"key":"10.14283\/jpad.2024.115_bib30","author":"Research Data Assistance Center (ResDAC)"},{"key":"10.14283\/jpad.2024.115_bib31","author":"Wise-Brown"},{"key":"10.14283\/jpad.2024.115_bib32","author":"Ochieng"},{"issue":"1","key":"10.14283\/jpad.2024.115_bib33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13195-023-01272-z","article-title":"Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis","volume":"15","author":"Mattke","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"10.14283\/jpad.2024.115_bib34","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3233\/JAD-190760","article-title":"Multi-national, cross-sectional survey of healthcare resource utilization in patients with all stages of cognitive impairment, analyzed by disease severity, country, and geographical region","volume":"75","author":"Khandker","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.14283\/jpad.2024.115_bib35","author":"Wallick"},{"key":"10.14283\/jpad.2024.115_bib36","first-page":"8154701","article-title":"Trends in healthcare resource use preceding diagnosis of Alzheimer's disease dementia","volume":"2023","author":"Abbass","year":"2023","journal-title":"Int J Alzheimers Dis"},{"key":"10.14283\/jpad.2024.115_bib37","author":"Jacobson"},{"key":"10.14283\/jpad.2024.115_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.dadm.2018.12.005","article-title":"Trends in health service use and potentially avoidable hospitalizations before Alzheimer's disease diagnosis: a matched, retrospective study of US Medicare beneficiaries","volume":"11","author":"Desai","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.14283\/jpad.2024.115_bib39","unstructured":"Seleri Assun\u00e7\u00e3o S, Brangman SA, Henderson JN, et al. ALUMNI AD study design: evaluation of subcutaneous gantenerumab in historically underrepresented US populations with early symptomatic Alzheimer's disease. Abstract presented at: The International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders Annual Meeting; March 31, 2023; Gothenburg, Sweden."},{"issue":"4","key":"10.14283\/jpad.2024.115_bib40","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3233\/JAD-210240","article-title":"Dementia care in diverse older adults in the U.S. deep south and the rest of the United States","volume":"83","author":"Pisu","year":"2021","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"10.14283\/jpad.2024.115_bib41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/geriatrics7020029","article-title":"Economic evaluation of healthcare resource utilization and costs for newly diagnosed dementia-related psychosis","volume":"7","author":"Rashid","year":"2022","journal-title":"Geriatrics (Basel)"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S227458072400654X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S227458072400654X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T21:14:40Z","timestamp":1737321280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S227458072400654X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S227458072400654X"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2024.115","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alzheimer's Disease Linkage to Real-World Evidence (AD-LINE) Study: Linking Claims Data to Phase 3 GRADUATE Study of Gantenerumab","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2024.115","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}